A share price of Precigen Inc [PGEN] is currently trading at $1.68, up 4.35%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PGEN shares have gain 10.53% over the last week, with a monthly amount glided 21.74%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th. In a post published today on Yahoo Finance, Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on November 18, 2022, and set its price target to $7. On February 25, 2021, Stifel initiated with a Buy rating and assigned a price target of $13 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $14 on February 22, 2021. B. Riley Securities initiated its recommendation with a Buy and recommended $10 as its price target on February 18, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on May 08, 2020, and assigned it a price target of $5.
Precigen Inc experienced fluctuations in its stock price throughout the past year between $0.81 and $1.88. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Precigen Inc [NASDAQ: PGEN] shares were valued at $1.68 at the most recent close of the market. An investor can expect a potential return of 257.14% based on the average PGEN price forecast.
Analyzing the PGEN fundamentals
Trailing Twelve Months sales for Precigen Inc [NASDAQ:PGEN] were 6.76M which represents -91.75% decline. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -3.35%, Pretax Profit Margin comes in at -3.3%, and Net Profit Margin reading is 1.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.14 and Total Capital is -0.47. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.6267 points at the first support level, and at 1.5733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7167, and for the 2nd resistance point, it is at 1.7533.
Precigen Inc [PGEN] reported earnings per share of -$0.08 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.08/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.08 per share as compared to estimates of -$0.1 per share, a difference of $0.02 representing a surprise of 20.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Precigen Inc [NASDAQ:PGEN] is 2.83. Also, the Quick Ratio is 2.83, while the Cash Ratio stands at 0.31. Considering the valuation of this stock, the price to sales ratio is 61.86, the price to book ratio is 2.92.
Transactions by insiders
Recent insider trading involved KIRK RANDAL J, Director, that happened on Dec 28 ’23 when 96686.0 shares were purchased. Director, KINDLER JEFFREY B completed a deal on Dec 28 ’23 to sell 96686.0 shares. Meanwhile, Director MITCHELL DEAN J bought 25000.0 shares on Sep 22 ’23.
